In Table 3, the Cox-regression model revealed that low-DAB2 expression in the pretreatment tumor of patients with ESCC achieved clinical complete remission could be an independent factor to identify patients with recurrence of ESCC (HR: 2.57, P=0.041). This evidence concerns the gene DAB2 and neoplasm.